Related by context. All words. (Click for frequent words.) 73 Unit Dose Budesonide 71 Oral NKTR 70 cannabinor 70 Traficet EN 70 diabetic neuropathic pain 70 PDE4 inhibitor 70 oral prodrug 69 tezampanel 68 mGluR5 NAM 68 NP2 Enkephalin 68 phase IIa clinical 68 torezolid phosphate 68 Panzem R 68 JAK inhibitor 68 Archexin 68 PS# [001] 68 PEG SN# 68 BEMA TM Fentanyl 68 teriflunomide 68 GSK# [001] 67 SinuNase TM 67 orally inhaled 67 RhuDex ® 67 Golimumab 67 Dapagliflozin 67 aclidinium bromide 67 CCX# 67 liposomal formulation 67 CRx 67 Bicifadine 67 vidofludimus 67 TPI ASM8 67 Azedra 67 pseudobulbar affect PBA 67 Zenvia ™ 67 R#/MEM # 67 NGX# 67 BEMA Buprenorphine 67 PRT# 67 TELINTRA 67 nebulized budesonide 67 Pimavanserin 67 ALGRX 67 TBC# 67 ARIKACE ™ 67 bicifadine 67 OXi# 66 KRN# 66 vascular disrupting agent 66 metaglidasen 66 GAMMAGARD 66 Neurodex 66 INCB# [001] 66 OMNARIS HFA 66 TG# [003] 66 aclidinium 66 elotuzumab 66 Denufosol 66 PEG Interferon lambda 66 class mGluR5 inhibitor 66 Phase Ib study 66 Phase 2a clinical 66 Aztreonam lysine 66 ularitide 66 MoxDuo 66 NVA# 66 generation purine nucleoside 66 Dyloject TM 66 nalbuphine ER 66 Phase IIa clinical 66 zileuton 66 GLYX 66 either acutely decompensated 66 Tezampanel 66 6R BH4 66 Aurexis 65 LEVADEX 65 huC# DM4 65 somatostatin analogue 65 PRX # 65 Vilazodone 65 virus HCV protease inhibitor 65 severe gastroparesis 65 CEQ# 65 XP# XP# 65 Phenoptin 65 phase IIb clinical 65 DDP# 65 tasocitinib 65 investigational compound 65 SILENOR TM 65 riociguat 65 subcutaneously administered 65 HQK 65 Synavive 65 ALVESCO HFA 65 opioid induced bowel dysfunction 65 investigational humanized monoclonal antibody 65 MAGE A3 ASCI 65 alvespimycin 65 Aerosurf 65 PSN# [002] 65 pertuzumab 65 AZD# 65 mertansine 65 Nanobody 65 fosbretabulin 65 peripherally acting 65 Phase 1a clinical 65 Chemophase 65 ISIS # 65 BAY #-# 65 Voreloxin 65 alvimopan 65 Ophena TM 65 CIMZIA ™ 65 ulimorelin 65 selective modulator 65 volociximab 65 Tyrima 64 selective androgen receptor modulator 64 LEVADEX TM 64 BRIM2 64 EXPAREL TM 64 Androxal TM 64 Trofex 64 BNC# 64 HCV protease inhibitor 64 tanespimycin 64 Mipomersen 64 Onalta 64 orally bioavailable 64 Cloretazine R VNP#M 64 LUNESTA TM 64 phase IIb 64 Tesetaxel 64 Bezielle 64 zonisamide SR 64 Aeroquin 64 investigational monoclonal antibody 64 ELACYT 64 rNAPc2 64 Relovair 64 YONDELIS 64 PEGylated Fab fragment 64 IMA# 64 anti amnesic 64 humanized anti 64 Aflibercept 64 EndoTAG TM -1 64 phase IIa 64 Iluvien ® 64 Phase Ib clinical 64 ATL/TV# 64 CIMZIA TM 64 anticancer compound 64 orally inhaled migraine 64 analgesic efficacy 64 Sym# 64 orally administered inhibitor 64 ALN PCS 64 Safinamide 64 Carfilzomib 64 dyskinesia PD LID 64 PRTX 64 adipiplon 64 SCH # 64 HuLuc# 64 polymerase inhibitor 64 CIMZIA TM certolizumab pegol 64 favorable pharmacokinetic profile 64 oral rivaroxaban 64 Onbrez Breezhaler 64 targeted radiotherapeutic 64 Elesclomol 64 Tarceva TM 64 intranasal formulation 64 ancrod 64 KNS # 64 Milnacipran 64 Radezolid 64 otelixizumab 64 Zelrix 64 BCX# 64 Ambrisentan 64 Levadex 64 IMPDH inhibitor 64 JAK2 inhibitor 64 Gabapentin GR 64 MoxDuo IR 64 Relivar 63 Azixa 63 Fx #A 63 FOLOTYN ® 63 AzaSite Plus 63 diarrhea predominant irritable 63 investigational oral 63 ALN TTR 63 ADX# 63 ZYBRESTAT 63 ILUVIEN ® 63 AeroLEF TM 63 CB2 selective receptor agonist 63 INCB# [002] 63 Spiegelmer ® 63 Aclidinium 63 telcagepant 63 LAS# [002] 63 incyclinide 63 BGC# 63 Solazed TM 63 IPX# 63 selective A2A adenosine receptor 63 ELND# 63 GSK# [002] 63 obatoclax 63 proteasome inhibitor 63 HCD# [002] 63 Pagoclone 63 HZT 63 atacicept 63 LymphoStat B 63 CTAP# Capsules 63 PSN# [001] 63 IRX 2 63 Empatic 63 Lu AA# 63 Menerba 63 Xanafide 63 Anticalin R 63 ENMD # 63 overactive bladder AA# 63 MGd 63 DermaVir Patch 63 PrevOnco 63 eosinophilic asthma 63 palonosetron 63 trial evaluating PRX# 63 Phase #b/#a trial 63 EOquin 63 desvenlafaxine succinate 63 evaluating tivozanib 63 PDX pralatrexate 63 eltrombopag 63 TNF Tumor Necrosis Factor 63 XOPENEX HFA 63 JZP 63 oxymorphone ER 63 Azedra TM 63 CXB# 63 ALN TTR# 63 Surfaxin LS 63 INC# 63 Diabetic Macular Edema DME 63 sorafenib tablets 63 inhaled formulation 63 Capesaris 63 dextromethorphan quinidine 63 CR# vcMMAE 63 torsemide ER 63 ruxolitinib 63 XL# XL# 63 intravenous acetaminophen 63 teduglutide 63 DexaSite 63 Panzem R NCD 63 Exelixis compounds 63 eprotirome 63 long acting muscarinic 63 PEG PAL 63 CorVue ™ 63 novel topoisomerase 63 visilizumab 63 Apoptone 63 PHX# 63 pharmacokinetics PK 63 novel VDA molecule 63 Corlux 63 APF# 63 Zenvia 63 dacetuzumab 63 LHRH antagonists 63 Phase Ib 63 Clonicel 63 PSMA ADC 63 VA# [002] 63 Lixivaptan 63 ganetespib 63 QVA# 63 salmeterol fluticasone 63 tezampanel NGX# 63 Guanilib 63 Dacogen injection 63 iSONEP 63 OvaRex R 63 EOquin TM 63 ciclesonide 63 LEVADEX ™ 63 MoxDuo TM IR 63 Zemiva ™ 63 sufentanil 63 Phase 1b trial 63 SNT MC# 63 CD3 monoclonal antibody 63 TOLAMBA 63 lexidronam injection 63 SinuNase 63 forodesine 62 GALNS 62 RGB # 62 RSD# 62 pharmacodynamic PD 62 ATL# [002] 62 ATL# [001] 62 Cleviprex TM clevidipine 62 TLK# 62 viral kinetics 62 SILENOR 62 Triolex 62 Q#IR 62 bronchodilatory 62 MEK inhibitor 62 HFA MDI 62 novel prodrug 62 pharmacodynamic properties 62 oral ridaforolimus 62 AEGR 62 OncoVEX GM CSF 62 Virulizin ® 62 refractory gout 62 zolmitriptan 62 radiation sensitizer 62 MTP inhibitor 62 Dalbavancin 62 injectable formulation 62 dimebon latrepirdine 62 LCP AtorFen 62 Phase 2b clinical 62 GRN# 62 PLK1 SNALP 62 aldehyde dehydrogenase ALDH2 deficiency 62 PEG uricase 62 Teriflunomide 62 PrevOnco ™ 62 USL# 62 TACI Ig 62 Numax 62 Prodarsan ® 62 agonist LABA 62 pharmacokinetic PK study 62 thymalfasin 62 lomitapide 62 pomalidomide 62 mapatumumab 62 RSD# oral 62 Alocrest 62 Acetavance TM intravenous acetaminophen 62 investigational drug 62 Daclizumab 62 TKB# 62 LUVENIQ 62 MYDICAR ® 62 XmAb# 62 cangrelor 62 phase IIb trial 62 Aliskiren 62 mecamylamine 62 novel oral anticoagulant 62 CORT # 62 leading oral taxane 62 NeuroSTAT ® 62 GFT# 62 Besivance 62 ospemifene 62 rHuPH# 62 Nexavar ® 62 Aloxi injection 62 XL# [003] 62 Fibrillex TM 62 Elotuzumab 62 delivers fluocinolone acetonide FA 62 HuMax EGFr 62 XL# anticancer compounds 62 GW# [003] 62 RELOVAIR ™ 62 pharmacokinetic PK 62 NKTR 62 Avanafil 62 Phase 1b clinical 62 ELND-#/AZD-# 62 Pegasys ® 62 IPL# 62 velafermin 62 prokinetic agent 62 ICA # 62 Microplasmin 62 tecarfarin 62 OncoGel 62 PNP inhibitor 62 Sphingomab 62 OMS# 62 PARI Pharma GmbH 62 CD# CEA 62 Duromist ™ 62 primary Restless Legs 62 BENLYSTA ® 62 XL# XL# XL# 62 efficacy tolerability 62 orally administered 62 Factor VIIa 62 rxRNA 62 mild vasodilator 62 methylnaltrexone 62 denufosol 62 MAXY G# 62 brand ciclesonide HFA 62 Tanespimycin 62 Phase 2b clinical trials 62 SURFAXIN r 62 EDEMA3 trial 62 reslizumab 62 compound INCB# 62 acetonide FA 62 Altastaph 62 ocular formulation 62 Anturol ® 62 trospium 62 Phase Ib clinical trials 62 Talabostat 62 catheter occlusion 62 Initiated Phase 62 Entereg R 62 Fibrin Pad 62 Methylnaltrexone 62 systemically administered 62 HGS ETR1 62 oral gallium 62 Phase 2a trial 62 lucinactant 62 BXT # 62 relapsing multiple sclerosis 62 schizophrenia CIAS 62 Darusentan 62 histone deacetylase HDAC inhibitor 62 thrombin inhibitor 62 MNTX 62 Zerenex 62 Excellarate TM 62 novel histone deacetylase 62 PD LID 62 seliciclib CYC# 62 Otelixizumab 62 AKT inhibitor 62 Onconase 62 Tarvacin TM 62 SAR# [004] 62 CYT# 62 CYT# potent vascular disrupting 62 Alexza Staccato 62 oral proteasome inhibitor 62 BEMA TM LA 62 custirsen 62 pradefovir 62 secondary efficacy endpoints 62 ORENCIA R 62 ACUROX ® 62 AEG# 62 UPLYSO 62 Polymer Microspheres 62 Inhalation Aerosol 62 preclinical efficacy 62 candidate deforolimus 62 receptor tyrosine kinase inhibitor 62 Zybrestat 62 non nucleoside inhibitor 61 M6G 61 sodium thiosulfate STS 61 dermal patch 61 EMBEDA ™ 61 Amrubicin 61 Elagolix 61 AeroLEF 61 HGS# 61 Locteron ® 61 CCX# B 61 Anturol TM 61 Phase IIa trial 61 tiapamil 61 Roflumilast 61 pharmacodynamic 61 Altropane 61 Hsp# Inhibitor 61 ruboxistaurin 61 TKM ApoB 61 Imprime PGG 61 sitaxsentan 61 sorafenib Nexavar 61 ONCONASE R 61 adenosine injection 61 IMiDs ® 61 Ozarelix 61 Tolvaptan 61 PEGylated anti 61 Ridaforolimus 61 Hsp# inhibitor 61 CYT# QbG# 61 pharmacokinetic profiles 61 lacosamide 61 Urocortin 2 61 Lisofylline LSF 61 Genz # 61 SILENOR ™ 61 topical gel formulation 61 candidate XP# 61 Phase III confirmatory 61 Alvesco R 61 LAB CGRP 61 synthetic retinoid 61 CYC# 61 MKC# MT 61 docetaxel Taxotere ® 61 opioid receptor antagonist 61 Proxinium TM 61 DAVANAT 61 HuMax CD# 61 OvaRex ® MAb 61 Locteron 61 NMDA antagonist 61 Cimzia TM 61 trastuzumab emtansine T DM1 61 carcinoid syndrome 61 mGluR5 negative 61 Amplimexon 61 Phase 2a Clinical Trial 61 investigational antiplatelet agent 61 VAPRISOL 61 postoperative ileus POI 61 Vaprisol 61 Phase IIa 61 SNRI 61 unique alkylating agent 61 PI3K/Akt pathway inhibitor 61 hypoxia activated prodrug 61 humanized monoclonal antibody 61 selective adenosine 61 ACZ# 61 MGCD# [001] 61 Ramoplanin 61 Arikace 61 PREZISTA r 61 PGL# 61 Pradefovir 61 immunomodulator 61 Diabetic Macular Edema 61 PDE4 inhibitors 61 faropenem medoxomil 61 GRNVAC1 61 inhaled TPI ASM8 61 ANYARA 61 Perifosine 61 Fulvestrant 61 urate lowering 61 talactoferrin 61 Enzastaurin 61 CBLC# 61 Trexima 61 tasimelteon 61 lurasidone 61 Lacosamide 61 DuraSite 61 alemtuzumab MS 61 aflibercept VEGF Trap 61 LEP ETU 61 serotonin norepinephrine reuptake inhibitor 61 Linagliptin 61 SYN# 61 Phase #b/#a clinical 61 Cannabinor 61 gallium containing 61 IV APAP 61 tolerated dose MTD 61 Parkinson disease levodopa induced 61 Glufosfamide 61 Vandetanib 61 Ticagrelor 61 CCR9 antagonist 61 oral transmucosal 61 varespladib 61 CTA# Injection 61 TYZEKA 61 INSPIRE Trial Phase III 61 Multiple Ascending Dose 61 RAPAFLO 61 OMNARIS Nasal Spray 61 prucalopride 61 PF # [001] 61 Phase 1b clinical trials 61 chemotherapy induced neutropenia 61 TRX1 61 maximally tolerated dose 61 Randomized Double blind 61 eniluracil 61 siRNA therapeutic 61 Serdaxin 61 Elacytarabine 61 BiTE antibody 61 SGX# 61 PXD# 61 Personalized Immunotherapy 61 CINQUIL 61 pan HDAC inhibitor 61 etanercept Enbrel 61 Trofex TM 61 Picoplatin 61 OMNARIS 61 sapacitabine CYC# 61 PA# [002] 61 MKC# MKC# PP 61 Plicera 61 Vicinium TM 61 LE DT 61 EP #R 61 limiting toxicity 61 TAFA# 61 vilazodone 61 cariprazine 61 ZYBRESTAT fosbretabulin 61 loxapine 61 crofelemer 61 cathepsin K inhibitor 61 AZILECT R 61 sapacitabine 61 Dasatinib 61 Neuradiab 61 Bortezomib 61 beta 1a 61 O PPDS 61 herpetic keratitis 61 Enkephalin 61 GlycoPEG GCSF 61 Syncria 61 ARIKACE 61 #D#C# 61 DU #b 61 CIMZIA R 61 elagolix 61 vapreotide acetate 61 SinuNase ™ 61 Cardio Vascu Grow 61 CRLX# 61 preclinical pharmacokinetic 61 selective inverse agonist 61 Chrysalin 61 Nanobody ® 61 phase 2a 61 iloperidone 61 Iloperidone 61 ongoing Phase 1b 61 molecular imaging radiopharmaceutical 61 preclinically 61 GATTEX ™ 61 Tarmogen 61 BEMA Granisetron 61 DOS# 61 Tasimelteon 61 HCV protease inhibitors 61 DEB# 61 Ecallantide 61 deforolimus 61 LymphoStat B belimumab 61 methylnaltrexone bromide 61 Sapacitabine 61 JAK1 61 Octreolin 61 xanthine oxidase inhibitor 61 LymphoStat B TM 61 omega interferon 61 dirucotide 61 Phase 2b trial 61 Omacetaxine 61 HspE7 61 Phase 2b study 61 Inhalation Solution 61 INCB# [003] 61 IL# PE#QQR 61 octreotide acetate 61 ORMD 61 acute migraine 61 multi kinase inhibitor 61 Fodosine 61 5 HT3 antagonist 61 small molecule Hedgehog 61 TRO# 61 TRANSDUR Sufentanil 60 ALVESCO R 60 ACTEMRA TM 60 axitinib 60 THR beta agonist 60 aripiprazole Abilify 60 inhibitor RG# 60 apoptosis inducer 60 CoFactor 60 ketolide antibiotic 60 efficacy endpoints 60 Hyphanox 60 acting muscarinic antagonist 60 BZL# 60 #ME# 60 Adlea 60 guanfacine extended release 60 subcutaneous formulation 60 MT# MEDI 60 forodesine hydrochloride 60 SLx 60 investigational atypical antipsychotic 60 cobiprostone 60 linaclotide 60 Tiotropium 60 dasatinib Sprycel ® 60 APD# 60 inhalation aerosol 60 Multimeric 60 CDP# 60 postoperative ileus 60 plasma kallikrein inhibitor 60 oral methylnaltrexone 60 brostallicin 60 Zemiva TM 60 Oracea TM 60 thetreatment 60 Anavex #-# 60 mecarbil 60 trastuzumab DM1 T DM1 60 XOMA 3AB 60 sodium glucose cotransporter 60 Pralatrexate 60 INVEGA ® 60 mGluR2 NAM 60 Prosaptide 60 oral antiviral 60 peritumoral brain edema 60 Frova ® 60 drug pipeline TAFA# 60 LY# [003] 60 apremilast 60 ELADUR 60 Zenvia Phase III 60 intravenously administered 60 fluocinolone acetonide 60 use transdermal sumatriptan 60 oral Factor Xa 60 #th Annual Interscience 60 LAF# 60 REGN# 60 ALKS 60 NPC 1C 60 D aspartate NMDA receptor 60 denileukin diftitox 60 Acetavance 60 FROVA 60 efficacy endpoint 60 trastuzumab DM1 60 Ofatumumab 60 CANCIDAS 60 generation antisense 60 canakinumab 60 selective antagonist 60 Lodotra TM 60 dimebon 60 constipation OIC 60 long acting bronchodilator 60 INT# [002] 60 erlotinib Tarceva ® 60 XL# XL# XL# XL# 60 Phase IIIb clinical 60 AIR# [001] 60 MYDICAR 60 baminercept 60 Asentar 60 PEG IFN 60 ostarine 60 R#/MEM 60 CINTREDEKIN BESUDOTOX 60 PKC# 60 Azedra ™ 60 REMINYL ® 60 CA4P 60 DP b# 60 Novolimus 60 SAR# [002] 60 brivaracetam 60 beta2 agonist 60 HCV NS5B polymerase 60 mixed dyslipidemia 60 MEK Inhibitor 60 Solzira TM 60 P#X# antagonist 60 tolerability profile 60 Meets Primary Endpoint 60 topically applied SEPA 60 ambrisentan 60 ATPace TM 60 markets Gelclair R 60 Intravenous CP 60 Eniluracil 60 Angiocept 60 safinamide 60 Atiprimod 60 Tarvacin 60 Ocrelizumab 60 TELCYTA 60 ApoB SNALP 60 ARC# [002] 60 adalimumab Humira 60 clevidipine 60 darapladib 60 iroxanadine 60 diabetic macular edema DME 60 Pirfenidone 60 MGCD# [002] 60 Dabigatran etexilate 60 regadenoson 60 Protexia R 60 glufosfamide 60 Naproxcinod 60 TREANDA 60 Exherin TM 60 valopicitabine 60 ceftazidime 60 dose limiting toxicities 60 Ciclesonide 60 2 methoxyestradiol 60 Phase 2a 60 dopamine partial agonist 60 SPIRIVA HandiHaler 60 granisetron 60 pharmacodynamic profiles 60 novel anticancer 60 tolerability profiles 60 budiodarone 60 Proellex TM 60 PEGylated interferon 60 Thiarabine 60 somatostatin analog 60 rFIXFc 60 Silodosin 60 Inhalation Powder 60 dutogliptin 60 Valdoxan 60 Pertuzumab 60 PTH analogue 60 laquinimod 60 liposome injection 60 ZOLINZA 60 ZACTIMA 60 octreotide implant 60 IMiDs R 60 systemic RNAi therapeutic 60 mg kg BID 60 Ketotransdel 60 entinostat 60 PEGylated interferon beta 1a 60 NXL# 60 relapsed multiple myeloma 60 RLY# 60 proton pump inhibitor PPI 60 Vicriviroc 60 Firazyr 60 telbivudine 60 Targretin 60 Phase IIa trials 60 EZN 60 Auxilium transmucosal film 60 pain palliation 60 TMC# [002] 60 sulodexide 60 mGluR2 positive 60 phase IIb study 60 icatibant 60 blinded randomized placebo controlled 60 Seliciclib 60 IAP inhibitor 60 neratinib 60 antiarrhythmic drug 60 Optiquel ™ 60 quetiapine fumarate 60 LHRH antagonist 60 rasagiline tablets 60 hour bronchodilation 60 Afatinib 60 JANUVIA 60 histamine dihydrochloride 60 Icatibant 60 CG# [003] 60 pharmacodynamic effects 60 rilonacept 60 ZYFLO R 60 Phase IIb clinical trials 60 HuMax CD4 60 bosentan 60 Proquin XR 60 AP# [003] 60 vorinostat 60 hypoxia selective 60 BHT DNA 60 pharmacokinetic profile 60 small molecule thrombopoietin 60 R sorafenib tablets 60 RhuDex 60 Shigamabs ® 60 Nanobodies 60 Anticalins 60 MKC# 60 lesinurad 60 milnacipran 60 OncoVEX 60 including eniluracil ADH 60 investigational pan BCR 60 VIAtab TM 60 inhaled corticosteroid 60 Serada 60 cilengitide 60 FM VP4 60 alfa 2a 60 EFAPROXYN 60 maximal tolerated 60 Rigel R# 60 pagoclone 60 AIR CF2 60 tubulin inhibitor 60 Belimumab 60 oral dihydropyrimidine dehydrogenase DPD 60 INS# [001] 60 Perforomist ™ Inhalation Solution 60 protein kinase inhibitor 60 inhaled corticosteroid ICS 60 solithromycin 60 Reverset 60 ACAPODENE 60 Serdaxin ® 60 AVONEX ® 60 Zoraxel TM 60 Rasagiline 60 Anturol 60 OMP #M# 60 Prednisporin 60 NEUGENE 60 metastatic HRPC 60 aflibercept 60 DUROS 60 APTIVUS r 60 Solzira 60 CD# antibody [001] 60 Clevudine 60 phase IIb III 60 EGS# 60 IAP inhibitors 60 PRX# 60 Linaclotide 60 naproxen esomeprazole magnesium 60 oxypurinol 60 Epratuzumab 60 oral beclomethasone dipropionate 60 Pegloticase 60 R roscovitine 60 direct thrombin inhibitors 60 IFN α 60 Viprinex TM 60 Onalta ™ 60 albiglutide 60 NU# [001] 60 Interferon alpha 60 tosedostat 60 generation nucleoside analog 60 vascular disrupting 59 investigational pharmacologically unique 59 Epanova 59 prochlorperazine 59 adecatumumab 59 Phase IIB 59 placebo controlled clinical 59 antiplatelet agent 59 docetaxel Taxotere R 59 Squalamine 59 Alpharadin 59 Zenvia TM 59 Curaxin CBLC# 59 colesevelam HCl 59 Pruvel 59 QNEXA 59 Ventavis 59 febuxostat 59 Ereska 59 mirtazapine 59 pharmacokinetic characteristics 59 initiate Phase IIa 59 roflumilast 59 Cimzia ® 59 neuroprotective properties